34 results about "Delayed hypersensitivity" patented technology

Procedure for obtaining Olea Europea extracts from Olea Europea leaves dried at less than 35° C. with alkanols at a low temperature and extract purificationNew pharmacological applications of Olea Europea extracts as an agent reinforcing cellular immunity and delayed hypersensitivity in healthy humans, activating and proliferating T-lymphocytes, Natural Killer cells, monocytes and granulocytes, and pro-inflammatory cytokins.

The invention provides an application of Incarvillea delavay alkali in preparing a drug for resisting autoimmune diseases and graft rejection diseases. Experiments show that the Incarvillea delavay alkali can inhibit human dendritic cell proliferation in vitro, prevent the human dendritic cells from accelerating the proliferation reaction of allogeneic T cells, and strengthen the capability of the human dendritic cell on secreting interleukin. Meanwhile, in the model of the experimental autoimmune disease cerebrospinal meningitis, the Incarvillea delavay alkali is applied in vivo so as to lower average clinical scores of mice and inhibit the spinal cord infiltration degree of mononuclear cells. In a heart transplantation experiment, the Incarvillea delavay alkali is applied in vivo to prolong the survival time of a transplanted heart. In a delayed hypersensitivity reaction model, the Incarvillea delavay alkali is applied in vivo to lower the auricle swelling degree of the mice. In-vivo and in-vitro results show that the Incarvillea delavay alkali has certain action on resisting autoimmune diseases and graft rejection diseases. The drug provided by the invention is a preparation composed of the Incarvillea delavay alkali which serves as an active ingredient, and a medicinal carrier. The drug can be in an oral agent form, an injection form, a suppository form or an external dosage form and the like.

The invention relates to a cyclic peptide which is provided with a residue fragment of -Val-Sta-Leu- and is used as immunosuppressive agents, and the synthesis process of the cyclic peptide (Ile-Ile-Pro-Pro-Tyr-Val-Sta-Leu) consists of 1) removing amino-protecting groups, 2) transpeptidase reaction, 3) the cutting of a peptide chain, 4) cyclization of the peptide chain. The cyclic peptide compounds which are provided with the residue fragment of Val-Sta-Leu- and used as immunosuppressive agents and have a high yield and a high purity can be obtained, and the immunosuppressive activity of the cyclic peptide compounds is higher. Through the experiments of the retarding effect of A3HS1 towards the delayed hypersensitivity of mice, the influence of phagocytic function of macrophages, and the retarding effect of the proliferation of lymphocytes, the A3HS1 shows a stronger immunosuppressive effect than HS-1, which reaches or surpasses the immunosuppressive of the positive contrast (cyclosporine).

An application of fumigaclavine C in treating Crohn's disease, ulcerative colitis, and T cell-related autoimmune diseases, such as delayed hypersensitivity, multiple sclerosis, insulin-dependent diabetes, etc, is disclosed.

The invention relates to the application of ginseng alkynol for preparing medicine treating delayed hypersensitivity diseases, in particular to the application of the ginseng alkynol for preparing the medicine treating contact dermatitis, the application of the ginseng alkynol for preparing the medicine treating hypersensitivity pneumonia, the application of the ginseng alkynol for preparing the medicine treating homograft rejection, and the application of the ginseng alkynol for preparing the medicine treating granulomatosis caused by pathogene in cells. The ginseng alkynol is used as main active ingredient used for treating the delayed hypersensitivity diseases, can obviously inhibit the diseases mediated by delayed hypersensitivity, has no obvious inhibition to immune organs and other cells, and is hopeful to be higher effective and lower toxic medicine used for treating the delayed hypersensitivity diseases.

The invention relates to cyclic peptide used as immunosuppressant and carried with -Pro-Sta-Tyr- residue fragment as well as ring (Ile-Ile-Pro-Sta-Tyr-Val-Pro-Leu). The synthesis process of the invention is as follows: (1) amino protecting group is removed; (2) synthesized peptide is completed; (3) peptide chain cutting is carried out; (4) peptide chain cyclization is completed. Therefore, a cyclic peptide compound, which has high yield, high purity and -Pro-Sta-Tyr- residue fragment and can be used as immunosuppressant, can be obtained; moreover, the compound has higher immunosuppression activity. The experiments on the inhibition of A2HS1 on mouse delayed hypersensitivity, the influence on the phagocytic capability of macrophage and the inhibition on lymphopoiesis show that the A2HS1 represents stronger natural immunosuppression than HS-1 and reaches or exceeds positive contrast (cyclosporin) immunosuppression.

A new immunosuppressive agent as glycyrol has significant immunosuppressive activity, thus is useful as an immunosuppressive agent to treat relative diseases, wherein the glycyrol is a coumestrol compound extracted from glycyrrhiza, which is a small molecular compound with novel chemical structure. Tests prove that the glycyrol can inhibit the increment of T lymphocyte induced by canavaline A and inhibit one-way mixed lymphocyte reaction (MLR), release the inflammatory symptom of delayed hypersensitivity and inhibit the homologous allogenic organ transplantation rejection. The glycyrol is a high-effective low-toxicity immunosuppressive agent, with small molecular weight and simple structure, which is easy to be modified and to prepare different drug agents, therefore, the compound is a new generation immunosuppressive agent.